Related Experiment Video
Updated: Jul 10, 2025
14:04
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
24.5K
Cloning, Purification, and Biophysical Characterization of FemB Protein from Methicillin-Resistant Staphylococcus
Anjini Gayatri Akkiraju1, Krishnam Raju Atcha2, Someswar Rao Sagurthi3
1Molecular Medicine Lab, Dept. of Genetics & Biotechnology, Osmania University, Hyderabad, Telangana, 500007, India.
Applied Biochemistry and Biotechnology
|November 22, 2023
Summary
Researchers explored Methicillin-resistant Staphylococcus aureus (MRSA) resistance mechanisms by studying FEM proteins. They discovered a novel hybrid molecule that shows greater MRSA inhibition than oxacillin.
Area of Science:
- Microbiology
- Biochemistry
- Medicinal Chemistry
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a significant global pathogen causing healthcare-associated and community-acquired infections.
- FEM proteins, encoded by the mecA gene, are implicated in antimicrobial resistance through unique peptidoglycan cross-linking, contributing to cell membrane stability.
Purpose of the Study:
- To express and purify FEM proteins for further study.
- To perform biophysical characterization of the FemB protein using in silico and in vitro methods.
- To identify novel compounds with potent MRSA inhibitory activity.
Main Methods:
- In silico and in vitro biophysical characterization of FemB protein.
- Expression and purification of FEM proteins.
- Biological screening assays for antimicrobial activity.
Main Results:
- Successful expression and purification of FEM proteins.
- Detailed biophysical characterization of FemB.
- Identification of a novel 1,2,3-triazole conjugated 1,3,4-oxadiazole hybrid molecule.
- The novel hybrid molecule demonstrated superior MRSA inhibition compared to oxacillin.
Conclusions:
- The study provides insights into FEM protein function in MRSA.
- A novel hybrid molecule targeting MRSA has been identified.
- This compound holds potential as a new therapeutic agent against MRSA infections.
